By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
The panelists generally agree that while Johnson & Johnson offers defensive characteristics and a growing dividend, its current premium valuation, unresolved talc litigation, and potential patent cliffs pose significant risks that could impact its dividend growth and overall performance.
Risk: Unresolved talc litigation and potential patent cliffs
Opportunity: Diversified product portfolio and strong R&D pipeline
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Johnson & Johnson is a leader in the pharmaceutical and medical device markets.
Consumers don't usually have many choices when it comes to their medical care.
Procter & Gamble (NYSE: PG) runs a great consumer staples business, and it is a Dividend King. But there's a nuance to consider when you look at the stock. And that not-so-small detail is why Johnson & Johnson (NYSE: JNJ) could be one of the best Dividend Kings to buy today. Here's what you need to know.
To become a Dividend King, a company must increase its dividend annually for at least 50 consecutive years. That's an incredible feat. A company can't produce that kind of consistency by accident. It requires a strong business model that is executed well in both good times and bad times. To be fair, many have done just that, with the current list including more than 50 companies.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
There are many types of businesses on the list, including industrials, utilities, financials, consumer staples, and healthcare, among others. That said, each business has its own dynamics. For example, industrial stocks have a history of being cyclical. Given today's market uncertainty, with some on Wall Street worried that inflation could lead to a recession, long-term investors should probably think carefully before buying a stock just because it is a Dividend King.
Essentially, you may want to focus on companies with products that sell well regardless of the economic environment. The go-to is often consumer staples companies, like Procter & Gamble. You aren't going to stop buying deodorant or soap. The company is one of the world's largest consumer staples companies, and it is generally considered an industry leader. The company enjoys strong brand loyalty, but consumers can still trade down.
It wouldn't be a mistake to buy P&G, noting that the stock appears reasonably valued right now and offers an attractive 3% dividend yield. However, a healthcare stock like Johnson & Johnson could be the best choice if you are worried about the economy.
Like P&G, J&J's products aren't optional. If you need healthcare, you are likely to buy the products and services you need. Not doing so could have dire consequences. However, J&J's business benefits from patent protections, notably in its pharmaceutical business. The medical device products it sells have material clout with healthcare providers and aren't likely to be easily displaced either. Meanwhile, J&J invests heavily in research and development to help ensure it remains an industry leader.
This isn't exactly a slam dunk. Johnson & Johnson's stock isn't nearly as attractively valued as P&G. For example, P&G's price-to-sales, price-to-earnings, and price-to-book ratios are all below their five-year averages right now. All of those valuation metrics are above J&J's five-year averages, which means you are paying a premium for a good business. That may not be as upsetting as you think when you consider that J&J's dividend has grown at a 5.7% annualized rate over the past decade, while P&G's dividend only grew at 2.4%. J&J's yield is roughly twice the broader market's, at a bit over 2.2%.
Of course, you could also switch gears and buy another healthcare company that's a Dividend King, such as drug maker Abbott (NYSE: ABT) or medical device company BD (NYSE: BDX). Neither would be a bad choice, but you get diversification across pharmaceuticals and medical devices in one investment by buying Johnson & Johnson. That gives J&J a stronger foundation to deal with adversity.
It could be a smart move to pay a premium for a Dividend King with a diversified, resilient business. That's particularly true given today's market and economic uncertainties. To be fair, J&J is facing some legal headwinds related to talcum powder it once produced, which may worry some investors. But management's ability to address that issue and continue to execute well across its diversified operations could also be viewed as an additional testament to the company's fundamental strength and ability to weather adversity.
Before you buy stock in Johnson & Johnson, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Johnson & Johnson wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $477,813! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,320,088!
Now, it’s worth noting Stock Advisor’s total average return is 986% — a market-crushing outperformance compared to 208% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of May 25, 2026. *
Reuben Gregg Brewer has positions in Procter & Gamble. The Motley Fool has positions in and recommends Abbott Laboratories. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"JNJ's premium valuation relative to historical averages and PG is not justified when litigation and post-2025 patent risks are factored in."
The article correctly flags JNJ's defensive moat via patents and non-discretionary healthcare demand, plus its 5.7% dividend CAGR versus PG's 2.4%. Yet it underplays two material risks: talc litigation liabilities remain unresolved and could pressure free cash flow beyond the modest reserves disclosed, while JNJ trades above five-year averages on P/S, P/E and P/B even as pharma peers face patent cliffs post-2025. PG's cheaper multiples and staples stability offer a clearer margin of safety if recession hits consumer healthcare spending. Diversification across devices and drugs is real but does not eliminate sector-specific regulatory and legal overhangs that PG largely avoids.
Litigation outcomes are already largely priced in and JNJ's R&D pipeline plus scale across three segments could deliver sustained 4-6% earnings growth that justifies the valuation premium in a prolonged slowdown.
"J&J is operationally resilient but currently overvalued relative to its defensive characteristics, making it a 'pay-up-for-quality' trade rather than a compelling value opportunity."
The article conflates 'recession-proof' with 'good value,' which are different things. Yes, J&J's pharma and devices sell regardless of economic cycles—that's true. But the article admits J&J trades at a *premium* to five-year averages while P&G trades at a *discount*. A 2.2% yield on an overvalued stock in a potential recession isn't obviously better than a 3% yield on undervalued P&G. The talc litigation is dismissed too casually; J&J faces $9B+ in reserves and ongoing appeals. Dividend growth (5.7% vs 2.4%) matters, but only if the stock doesn't compress on valuation reset—a real risk if rates stay elevated or earnings disappoint.
If recession hits hard, J&J's defensive moat and pricing power could justify the premium valuation, and its 60-year dividend track record suggests management will protect it even under pressure—making the 5.7% growth rate the real signal, not the current yield.
"JNJ’s current valuation premium is unjustified given the heightened legal risk and the loss of its stable consumer-staples revenue base following the Kenvue separation."
While the article correctly highlights JNJ's defensive profile, it glosses over the structural drag of the Kenvue spin-off and the ongoing talc litigation. JNJ is no longer the diversified consumer-healthcare titan it once was; it is now a pure-play medtech and pharma entity, which historically carries higher binary risk. Trading at a premium to its five-year average while facing an massive, unresolved liability overhang makes the 'Dividend King' status a secondary concern to potential balance sheet impairment. Investors should focus on the R&D pipeline's ability to offset patent cliffs, rather than just dividend history, as the stock's valuation is currently pricing in a flawless legal resolution that is far from guaranteed.
The market may be pricing in a worst-case legal settlement, meaning any positive resolution or containment of the talc liabilities could trigger a significant valuation re-rating.
"JNJ remains a high-quality, defensive dividend grower, but valuation and unresolved liabilities may cap upside versus cheaper peers."
Johnson & Johnson offers a durable defensive platform and a growing dividend, but the bull case hinges on a steady path of cash flows and resilience. The strongest counterview is that JNJ trades at a premium to peers (and to its five-year averages) with limited upside if growth slows or talc-related liabilities linger longer than expected. The unresolved litigation adds a non-operating risk that could dent earnings power or capex flexibility, even as R&D and a broad pipeline provide optionality. The dividend yield is not the highest among defensives, and peers like Abbott or BD offer similar defensiveness with different risk profiles. In a risk-off regime, multiple expansion risk could cap total returns over 12–24 months.
JNJ's valuation premium could prove painful if litigation costs rise or growth decelerates; in a risk-off environment, cheaper defensives with similar stability might outperform despite the brand.
"Patent cliffs threaten JNJ dividend growth more than litigation or PG's cheaper valuation."
Claude's yield comparison misses JNJ's lower earnings volatility post-spin-off compared to PG's consumer cyclicality. Patent cliffs in pharma, unmentioned here, pose a greater threat to the 5.7% dividend CAGR than talc reserves alone. A valuation reset might coincide with R&D failures, amplifying downside beyond what PG's discount multiple implies for recession scenarios.
"Patent cliffs don't differentiate JNJ from pharma peers; talc litigation does, and that's the argument to make."
Grok conflates two separate risks. Patent cliffs are *sector-wide* and affect JNJ's peers equally—not a JNJ-specific bear case. Talc reserves ($9B disclosed) are JNJ-specific. If talc is the real tail risk, say so directly rather than pivoting to pharma cyclicality that applies to Eli Lilly and Novo too. The earnings volatility claim post-spin needs numbers: PG's consumer exposure is real, but JNJ's device segment is also cyclical to elective procedures.
"JNJ’s valuation is vulnerable to interest rate sensitivity and medtech-specific operational risks that outweigh the dividend growth narrative."
Claude, you’re missing the forest for the trees on the medtech side. JNJ’s device segment isn't just 'cyclical'; it’s highly sensitive to hospital staffing shortages and elective surgery backlogs, which are distinct from pharma patent cliffs. While you and Grok debate the talc liability, you’re ignoring that JNJ is effectively a 'bond proxy' with equity risk. If the 10-year Treasury yield stays above 4%, that 5.7% dividend growth is irrelevant if the multiple compresses toward 14x.
"The bond-proxy view undervalues JNJ's talc-tail risk and device-sector cyclicality, which can prevent multiple expansion even with dividend growth."
Gemini paints JNJ as a bond proxy, which oversimplifies. The devices and hospital-service exposure introduce cyclicality that can surprise in a downturn, and talc liabilities create tail-risk that can magnify drawdowns in covenants or capex flexibility. Even with a 5.7% dividend CAGR, a higher-for-longer rate backdrop and any FCF pressure from legal costs could keep a 14x multiple out of reach. The 'bond proxy' thesis may underestimate equity risk.
The panelists generally agree that while Johnson & Johnson offers defensive characteristics and a growing dividend, its current premium valuation, unresolved talc litigation, and potential patent cliffs pose significant risks that could impact its dividend growth and overall performance.
Diversified product portfolio and strong R&D pipeline
Unresolved talc litigation and potential patent cliffs